Last reviewed · How we verify
imiquimod cream, 3.75%
imiquimod cream, 3.75% is a Immunomodulator Small molecule drug developed by Actavis Mid-Atlantic LLC. It is currently in Phase 3 development for Actinic keratosis, Superficial basal cell carcinoma, External genital warts.
Imiquimod cream works by activating the immune system to fight off abnormal cell growth.
Imiquimod cream works by activating the immune system to fight off abnormal cell growth. Used for Actinic keratosis, Superficial basal cell carcinoma, External genital warts.
At a glance
| Generic name | imiquimod cream, 3.75% |
|---|---|
| Sponsor | Actavis Mid-Atlantic LLC |
| Drug class | Immunomodulator |
| Target | TLR7, TLR8 |
| Modality | Small molecule |
| Therapeutic area | Dermatology |
| Phase | Phase 3 |
Mechanism of action
It does this by binding to toll-like receptor 7 (TLR7) and toll-like receptor 8 (TLR8) on dendritic cells, which then stimulates the production of interferon-alpha and other cytokines that help to eliminate abnormal cells.
Approved indications
- Actinic keratosis
- Superficial basal cell carcinoma
- External genital warts
Common side effects
- Local skin reactions
- Flu-like symptoms
- Headache
- Fatigue
- Pruritus
Key clinical trials
- Characterization of the Toll-like Receptor 7-agonist Imiquimod 3.75% As a New Surrogate Model of Itch (NA)
- Earliest Stage Treatment of Aktinic Keratosis With Imiquimod 3.75% Cream (PHASE4)
- Effectiveness of Imiquimod Topical Cream in Early Stage Cutaneous T-cell Lymphoma (NA)
- Genomic Markers Before and After Treatment of Actinic Keratosis With Imiquimod 3.75% Cream (PHASE2)
- Study Comparing Imiquimod Cream, 3.75% to Zyclara® (Imiquimod) Cream, 3.75% in the Treatment of Actinic Keratosis (PHASE3)
- Treatment of Actinic Keratoses of the Face With Imiquimod 3.75% Cream Followed by Photodynamic Therapy (PHASE4)
- Clinical Study to Evaluate the Bioequivalence of Two Imiquimod Cream 3.75% Formulations in Patients With Actinic Keratosis. (PHASE1)
- Potential Effect of Topical Imiquimod on Atrial Ectopy in Patients With Actinic Keratosis (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- imiquimod cream, 3.75% CI brief — competitive landscape report
- imiquimod cream, 3.75% updates RSS · CI watch RSS
- Actavis Mid-Atlantic LLC portfolio CI
Frequently asked questions about imiquimod cream, 3.75%
What is imiquimod cream, 3.75%?
How does imiquimod cream, 3.75% work?
What is imiquimod cream, 3.75% used for?
Who makes imiquimod cream, 3.75%?
What drug class is imiquimod cream, 3.75% in?
What development phase is imiquimod cream, 3.75% in?
What are the side effects of imiquimod cream, 3.75%?
What does imiquimod cream, 3.75% target?
Related
- Drug class: All Immunomodulator drugs
- Target: All drugs targeting TLR7, TLR8
- Manufacturer: Actavis Mid-Atlantic LLC — full pipeline
- Therapeutic area: All drugs in Dermatology
- Indication: Drugs for Actinic keratosis
- Indication: Drugs for Superficial basal cell carcinoma
- Indication: Drugs for External genital warts
- Compare: imiquimod cream, 3.75% vs similar drugs
- Pricing: imiquimod cream, 3.75% cost, discount & access